.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers recently presented findings from the TOCEM trial, which evaluated contrast reactions in CEM over three years of annual screening. The prospective study monitored 1,651 women with a personal history of breast cancer who received a total of 3,873 injections of iopamidol. As contrast-enhanced mammography (CEM) becomes a more frequent supplemental screening tool, understanding its safety profile is essential for radiologists and oncologists alike.
The results showed that only 38 out of 3,873 injections resulted in a reaction, equating to a low overall rate of 0.98%. Specifically, allergic-like reactions were the most common, appearing in 0.65% of cases. Most of these (80%) were cutaneous, such as hives or rashes. Additionally, the study noted that patients receiving contrast for the first time had a significantly higher risk (1.96%) compared to those with prior uneventful exposure (0.42%).
Furthermore, the study identified five delayed allergic-like reactions. These symptoms appeared between one and seven days after the initial administration. Only two reactions were severe enough to prevent the completion of imaging. However, most reactions were mild, although 60% of those with allergic-like symptoms required medication for management. Consequently, CEM remains a safe supplemental screening tool for high-risk populations. Clinicians should still remain vigilant for delayed cutaneous symptoms even after the patient leaves the clinic.
Based on the TOCEM trial data, the overall incidence of contrast reactions is low, at approximately 0.98% across thousands of injections.
Yes. The study found that contrast-naïve patients had a significantly higher reaction rate (1.96%) compared to those with prior uneventful exposure (0.42%).
Delayed reactions are primarily cutaneous, such as hives or rashes, and can occur between one and seven days after the procedure.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Healthcare providers should perform their own independent assessment. Refer to the latest local and national guidelines for clinical practice.
References
Gu L et al. Prevalence of Acute and Delayed Contrast Reactions With Multiple Exposures to Contrast-Enhanced Mammography-Experience From the TOCEM Trial. J Breast Imaging. 2026 Feb 09. doi: undefined. PMID: 41661649.
Zanardo M, et al. Adverse events in contrast-enhanced mammography: a systematic review and meta-analysis. European Radiology. 2023;33(10):6741-6751.
American College of Radiology. ACR Manual on Contrast Media. 2023. URL: https://www.acr.org/Clinical-Resources/Contrast-Manual
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study of 3,873 injections reveals that contrast reactions in CEM are rare (0.98%), with most being mild allergic-like cutaneous events....
7 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
